Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
Aciclovir
GlaxoSmithKline (Ireland) Limited
J05AB; J05AB01
Aciclovir
200 milligram(s)
Dispersible tablet
Product subject to prescription which may not be renewed (A)
Nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir
Marketed
1996-12-03
Reason for Update: Type II C.1.4 Update to GDS 30 and Minor labelling findings Market: IE Agenc Approval date: TBA Text date: 21/04/2020 Text Issue and Draft No.: Issue 3, Draft 1 (GSK LOGO) PACKAGE LEAFLET: INFORMATION FOR THE USER ZOVIRAX 200 MG DISPERSIBLE TABLETS ACICLOVIR READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1 What Zovirax is and what it is used for 2 What you need to know before you take Zovirax 3 How to take Zovirax 4 Possible side effects 5 How to store Zovirax 6 Contents of the pack and other information 1 WHAT ZOVIRAX IS AND WHAT IT IS USED FOR Zovirax 200 mg Dispersible Tablets (called ‘Zovirax’ in this leaflet) contains a medicine called aciclovir. This belongs to a group of medicines called antivirals. It works by stopping the growth of viruses. Zovirax 200 mg Dispersible Tablets can be used to: treat chickenpox treat shingles, and when started right after the rash appears, it can help reduce the nerve pain that can exist after the shingles rash has cleared treat cold sores, genital herpes and other herpes simplex infections (but not to be used to treat herpes simplex infections in newborn infants or severe herpes simplex infections in children whose immune systems work less well, which means their bodies are less able to fight infections) stop cold sores and genital herpes returning after you have had them prevent cold sores and genital herpes in people whose immune systems work less well. 2 WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZOVIRAX DO NOT USE ZOVIRAX IF: Διαβάστε το πλήρες έγγραφο
Health Products Regulatory Authority 21 May 2021 CRN00CD8H Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zovirax 200 mg Dispersible Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg aciclovir Excipient(s) with known effect: This product contains sodium as Sodium starch glycollate, see section 4.4 For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Dispersible Film-coated tablet. Zovirax 200 mg tablets are white, round film-coated tablets branded with 'GXCF3' on one side and plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zovirax Tablets 200 mg are indicated for the treatment of Herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital Herpes (excluding neonatal HSV and severe HSV infections in immunocompromised children). Zovirax Tablets 200 mg are indicated for the suppression (prevention of recurrences) of recurrent Herpes simplex infections in immunocompetent patients. Zovirax Tablets 200 mg are indicated for the prophylaxis of Herpes simplex infections in immunocompromised patients. Zovirax Tablets 200 mg are indicated for the treatment of Varicella (chickenpox) and Herpes zoster (shingles) infections. Studies have shown that early treatment of shingles with Zovirax has a beneficial effect on pain and can reduce the incidence of post-herpetic neuralgia (zoster- associated pain). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION DOSAGE FOR TREATMENT OF HERPES SIMPLEX IN ADULTS. For treatment of Herpes simplex infections, 200 mg Zovirax should be taken five times daily at approximately four-hourly intervals omitting the night time dose. Treatment should continue for 5 days, but in severe initial infections may have to be extended. In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut the dose can be doubled to 400 mg or, alternatively, intravenous dosing could be considered. Dosing should begin as early Διαβάστε το πλήρες έγγραφο